RU2472804C2 - Способ удаления вирусов из жидкой композиции, содержащей фактор vii - Google Patents

Способ удаления вирусов из жидкой композиции, содержащей фактор vii Download PDF

Info

Publication number
RU2472804C2
RU2472804C2 RU2006118024/10A RU2006118024A RU2472804C2 RU 2472804 C2 RU2472804 C2 RU 2472804C2 RU 2006118024/10 A RU2006118024/10 A RU 2006118024/10A RU 2006118024 A RU2006118024 A RU 2006118024A RU 2472804 C2 RU2472804 C2 RU 2472804C2
Authority
RU
Russia
Prior art keywords
factor vii
range
recombinant factor
liquid composition
polypeptide
Prior art date
Application number
RU2006118024/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2006118024A (ru
Inventor
Йеспер КРИСТЕНСЕН
Эрик ХАЛКЕР
Турид ПРЕУСС
Томас Будде ХАНСЕН
Лене Вэделе Мадсен ТОМОДА
Нина ЙОХАНСЕН
Original Assignee
Ново Нордиск Хелс Кеа Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34639198&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2472804(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ново Нордиск Хелс Кеа Аг filed Critical Ново Нордиск Хелс Кеа Аг
Publication of RU2006118024A publication Critical patent/RU2006118024A/ru
Application granted granted Critical
Publication of RU2472804C2 publication Critical patent/RU2472804C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • C12N2740/13063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2006118024/10A 2003-12-01 2004-12-01 Способ удаления вирусов из жидкой композиции, содержащей фактор vii RU2472804C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301775 2003-12-01
DKPA200301775 2003-12-01
PCT/EP2004/053206 WO2005054275A2 (en) 2003-12-01 2004-12-01 Nanofiltration of factor vii solutions to remove virus

Publications (2)

Publication Number Publication Date
RU2006118024A RU2006118024A (ru) 2008-01-10
RU2472804C2 true RU2472804C2 (ru) 2013-01-20

Family

ID=34639198

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006118024/10A RU2472804C2 (ru) 2003-12-01 2004-12-01 Способ удаления вирусов из жидкой композиции, содержащей фактор vii

Country Status (14)

Country Link
US (8) US20070142625A1 (https=)
EP (3) EP2275432A1 (https=)
JP (3) JP4874806B2 (https=)
KR (1) KR101234170B1 (https=)
CN (3) CN1890257A (https=)
AU (1) AU2004294403A1 (https=)
BR (1) BRPI0416950B8 (https=)
CA (1) CA2545474A1 (https=)
DK (1) DK1711513T3 (https=)
ES (2) ES2507091T3 (https=)
PL (1) PL1711513T3 (https=)
PT (1) PT1711513E (https=)
RU (1) RU2472804C2 (https=)
WO (1) WO2005054275A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2526494C1 (ru) * 2013-03-19 2014-08-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Челябинская государственная медицинская академия" Министерства здравоохранения Российской Федерации" (ГБОУ ВПО ЧелГМА Минздрава России) Способ удаления вируса иммунодефицита человека из спермы мужчины

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4874806B2 (ja) 2003-12-01 2012-02-15 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 液体因子ｖｉｉ組成物のウイルス濾過
DE102005037824A1 (de) * 2005-08-08 2007-02-15 Zlb Behring Gmbh Neuartiges Virusreduktionsverfahren
ES2811526T3 (es) 2010-12-30 2021-03-12 Lab Francais Du Fractionnement Glicoles como agentes de inactivación de patógenos
KR20140022845A (ko) 2011-03-25 2014-02-25 제넨테크, 인크. 신규 단백질 정제 방법
BR112014031842B1 (pt) * 2012-06-21 2020-09-15 Baxalta GmbH Método para remover um contaminante viral de uma preparação
TWI641382B (zh) * 2013-01-31 2018-11-21 韓美藥品股份有限公司 於包含因子ｖｉｉ之組成物中使病毒失活之方法
WO2015073633A1 (en) * 2013-11-15 2015-05-21 Genentech, Inc. Methods for viral inactivation using eco-friendly detergents
CN105435644A (zh) * 2014-09-29 2016-03-30 中国石油化工股份有限公司 一种纳滤膜及其制备方法
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
EP3833381B1 (en) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration
US20230287335A1 (en) * 2020-07-30 2023-09-14 Amgen Inc. Cell culture media and methods of making and using the same
USD1013170S1 (en) 2020-10-29 2024-01-30 Cilag Gmbh International Surgical instrument assembly

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0131740A2 (en) * 1983-07-14 1985-01-23 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
EP0549964A2 (de) * 1991-12-24 1993-07-07 Octapharma Ag Verfahren zur Herstellung eines virusinaktivierten Prothrombin-komplex-Konzentrats (PPSB)
WO1998037086A1 (en) * 1997-02-24 1998-08-27 Stichting Sanquin Bloedvoorziening Method for removing viruses from protein solution by nanofiltration

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3100501A (en) 1960-12-23 1963-08-13 Crane Co Removable head and seat ball valve construction
JPS6033009B2 (ja) * 1978-12-29 1985-07-31 三菱電機株式会社 マイクロ波発振装置
US4456591A (en) 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
WO1992015686A1 (en) 1991-02-28 1992-09-17 Zymogenetics, Inc. Modified factor vii
DK38293D0 (da) 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
SE9500724D0 (sv) * 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
US5677162A (en) 1995-05-01 1997-10-14 New York Blood Center, Inc. Method for activating prothrombin to thrombin
AT406019B (de) * 1995-05-08 2000-01-25 Immuno Ag Verfahren zur herstellung eines arzneimittels enthaltend ein oder mehrere plasmaderivate
AT405608B (de) * 1997-04-08 1999-10-25 Immuno Ag Verfahren zur inaktivierung von pathogenen, insbesondere von viren, in einem biologischen material
AT407159B (de) * 1997-06-13 2001-01-25 Immuno Ag Verfahren zur abreicherung von viralen und molekularen pathogenen aus einem biologischen material
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
ATA159597A (de) * 1997-09-19 2000-09-15 Immuno Ag Präparat zur behandlung von blutgerinnungsstörungen
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US5981254A (en) * 1997-10-30 1999-11-09 Haemacure Corporation Process for producing thrombin from plasma
CA2308610A1 (en) 1997-11-05 1999-05-14 Welfide Corporation Heparin cofactor ii preparation and process therefor
FI106465B (fi) 1998-06-10 2001-02-15 Suomen Punainen Risti Veripalv Menetelmä virusturvallisten farmaseuttisten koostumusten valmistamiseksi
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
EP1198565A1 (en) 1999-07-07 2002-04-24 Maxygen Aps A method for preparing modified polypeptides
JP4451514B2 (ja) 1999-08-24 2010-04-14 財団法人化学及血清療法研究所 血液凝固第ｖｉｉ因子改変体
CA2739933A1 (en) 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
JP4455802B2 (ja) 2000-05-03 2010-04-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト第ｖｉｉ凝固因子変異型
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
WO2002022776A2 (en) 2000-09-13 2002-03-21 Novo Nordisk A/S Human coagulation factor vii variants
BR0114373A (pt) 2000-10-02 2004-02-17 Novo Nordisk As Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
CZ20032454A3 (en) 2001-03-22 2004-03-17 Novo Nordisk Health Care Ag Coagulation factor vii derivative
CZ2004427A3 (cs) 2001-09-27 2004-08-18 Novoánordiskáhealthácareáag Polypeptidy lidského koagulačního faktoru VII
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
JP2005512524A (ja) 2001-11-02 2005-05-12 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固第ｖｉｉ因子ポリペプチド
DE10211632A1 (de) 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
WO2003093465A1 (en) 2002-04-30 2003-11-13 Maxygen Holdings Ltd. FACTOR VII OR VIIa POLYPEPTIDE VARIANTS
CA2484173A1 (en) 2002-04-30 2003-11-13 Merck & Co., Inc. 4-azasteroid derivatives as androgen receptor modulators
RS20050051A (sr) 2002-07-23 2007-06-04 Bio-Products & Bio Engineering Ag., Farmaceutski aktivni sastojak preparata i medikamenata koji sadrže trombin ili imaju mogućnost stvaranja trombina
ATE428440T1 (de) 2002-07-23 2009-05-15 Bio & Bio Licensing Sa Thrombingenerierfähige und thrombinhaltige pharmazeutische wirkstoffzubereitungen und arzneimittel
CA2840692A1 (en) 2002-09-30 2004-04-08 Bayer Healthcare Llc Fvii or fviia variants having increased clotting activity
WO2005002615A1 (en) * 2003-07-01 2005-01-13 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
JP4874806B2 (ja) * 2003-12-01 2012-02-15 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 液体因子ｖｉｉ組成物のウイルス濾過
FR2901796A1 (fr) 2006-05-31 2007-12-07 Lab Francais Du Fractionnement Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
FR2904558B1 (fr) 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
FR2910786B1 (fr) 2006-12-29 2017-08-11 Laboratoire Francais Du Fractionnement Et Des Biotechnologies (Lfb) "procede d'extraction d'une proteine presente dans du lait"
FR2947181B1 (fr) 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii
EP2687595B1 (en) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0131740A2 (en) * 1983-07-14 1985-01-23 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
EP0549964A2 (de) * 1991-12-24 1993-07-07 Octapharma Ag Verfahren zur Herstellung eines virusinaktivierten Prothrombin-komplex-Konzentrats (PPSB)
WO1998037086A1 (en) * 1997-02-24 1998-08-27 Stichting Sanquin Bloedvoorziening Method for removing viruses from protein solution by nanofiltration

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BURNOUF T. et al., "Nano filtration of plasma-derived biopharmaceutical products", Haemophilia. 2003 Jan; 9(1):24-37. *
HOROWITZ B. et al., "Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma", Vox Sang. 1998; 74 Suppl 1:203-6. *
TOMOKIYO K. et al., "Large-scale production and properties of human plasma-derived activated Factor VII concentrate", Vox Sang. 2003 Jan; 84(1):54-64. *
TOMOKIYO K. et al., "Large-scale production and properties of human plasma-derived activated Factor VII concentrate", Vox Sang. 2003 Jan; 84(1):54-64. BURNOUF T. et al., "Nano filtration of plasma-derived biopharmaceutical products", Haemophilia. 2003 Jan; 9(1):24-37. HOROWITZ B. et al., "Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma", Vox Sang. 1998; 74 Suppl 1:203-6. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2526494C1 (ru) * 2013-03-19 2014-08-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Челябинская государственная медицинская академия" Министерства здравоохранения Российской Федерации" (ГБОУ ВПО ЧелГМА Минздрава России) Способ удаления вируса иммунодефицита человека из спермы мужчины

Also Published As

Publication number Publication date
US20070142625A1 (en) 2007-06-21
US20190032026A1 (en) 2019-01-31
EP3594222B1 (en) 2022-08-03
JP2011173889A (ja) 2011-09-08
CN106916802B (zh) 2022-03-25
KR101234170B1 (ko) 2013-02-18
BRPI0416950A (pt) 2007-02-13
CN106916802A (zh) 2017-07-04
CN1890257A (zh) 2007-01-03
BRPI0416950A8 (pt) 2019-01-22
CA2545474A1 (en) 2005-06-16
EP2275432A1 (en) 2011-01-19
JP5666359B2 (ja) 2015-02-12
ES2926359T3 (es) 2022-10-25
BRPI0416950B8 (pt) 2021-05-25
BRPI0416950B1 (pt) 2019-05-28
ES2507091T3 (es) 2014-10-14
US20170022482A1 (en) 2017-01-26
US9102762B2 (en) 2015-08-11
US20150299685A1 (en) 2015-10-22
WO2005054275A2 (en) 2005-06-16
JP2007537994A (ja) 2007-12-27
US20200248150A1 (en) 2020-08-06
US20080274534A1 (en) 2008-11-06
CN102351953B (zh) 2017-05-10
EP3594222A1 (en) 2020-01-15
JP4874806B2 (ja) 2012-02-15
US20220064605A1 (en) 2022-03-03
RU2006118024A (ru) 2008-01-10
EP1711513B1 (en) 2014-07-02
JP2012021007A (ja) 2012-02-02
EP1711513A2 (en) 2006-10-18
AU2004294403A1 (en) 2005-06-16
CN102351953A (zh) 2012-02-15
PL1711513T3 (pl) 2014-12-31
US20120115204A1 (en) 2012-05-10
DK1711513T3 (da) 2014-09-15
PT1711513E (pt) 2014-10-02
KR20070001887A (ko) 2007-01-04
WO2005054275A3 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
US20220064605A1 (en) Virus Filtration of Liquid Factor VII Compositions
CA2192683C (en) Filtration
ES3000382T3 (en) Methods of purifying recombinant adamts13 and other proteins and compositions thereof
AU601984B2 (en) Process for producing biologically active plasminogen activator
CN102718859A (zh) 通过分级洗脱从阴离子交换材料中纯化批量凝血因子vii多肽
AU2012201036B2 (en) Virus filtration of liquid factor VII compositions
MXPA06005967A (en) Nanofiltration of factor vii solutions to remove virus
AU682274C (en) Filtration

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner